Related Experiment Video
Updated: Jan 10, 2026
Using 22C3 Anti-PD-L1 Antibody Concentrate on Biopsy and Cytology Samples from Non-small Cell Lung Cancer Patients
Published on: September 25, 2018
Treatment-Related Adverse Events of Antibody-Drug Conjugate Monotherapy in Non-Small Cell Lung Cancer: A Systematic
Yuwei Li1,2, Linjing Zhou2,3, Sini Li2
1Postgraduate Training Base Alliance of Wenzhou Medical University, Hangzhou, Zhejiang, China.
Background:
Antibody-drug conjugates (ADCs) have demonstrated promising efficacy in several prospective clinical studies, offering new possibilities for the treatment of non-small cell lung cancer (NSCLC). Consequently, understanding the toxicity profile associated with ADCs is of critical importance.
Methods:
A comprehensive search was performed across PubMed, Embase, Cochrane Library, and ClinicalTrials.gov for studies on ADC monotherapy in NSCLC. Data extraction prioritized treatment-related adverse events (TRAEs), drug-related adverse events (AEs), or treatment-emergent adverse events (TEAEs). Incidences were pooled using a random-effects model.
Results:
Thirteen studies including 1566 NSCLC patients were analyzed. The pooled incidence of all-grade TRAEs was 93.67%. Grade ≥ 3 TRAEs occurred in 38.74%, and serious TRAEs in 15.89%. Discontinuation and mortality rates were 9.52% and 0.63%. Hematologic toxicity was common among grade ≥ 3 TRAEs. Additionally, 20 fatal TRAEs were mainly associated with respiratory toxicity. Subgroup analysis for adverse events of special interest (AESIs) showed that Trastuzumab deruxtecan was more likely to cause grade ≥ 3 pneumonitis or interstitial lung disease (ILD), while TROP2-targeted ADCs were prone to high-grade stomatitis and ocular toxicity.
Conclusion:
The overall incidence of TRAEs with ADC monotherapy in NSCLC is high, but most are Grade 1 or 2 and overall safety is manageable. Importantly, fatal TRAEs were mainly respiratory in this study, requiring clinical vigilance. Grade ≥ 3 AESIs should also be closely monitored.
Registration:
This study was registered at INPLASY (ID: INPLASY2023120046).
Insights
Antibody-drug conjugates (ADCs) show promise for non-small cell lung cancer (NSCLC) treatment. While most toxicities are manageable, fatal events often involve respiratory issues, necessitating careful monitoring of serious adverse events.
Area of Science:
- Oncology
- Pharmacology
- Clinical Trials
Background:
- Antibody-drug conjugates (ADCs) offer novel therapeutic strategies for non-small cell lung cancer (NSCLC).
- Understanding the toxicity profiles of ADCs is crucial for safe and effective clinical application in NSCLC.
- This study addresses the critical need to evaluate the safety and adverse events associated with ADC monotherapy in NSCLC patients.
Purpose of the Study:
- To comprehensively assess the incidence and nature of treatment-related adverse events (TRAEs) associated with ADC monotherapy in non-small cell lung cancer (NSCLC).
- To identify specific toxicities and risk factors, including fatal events and adverse events of special interest (AESIs), in NSCLC patients treated with ADCs.
- To provide insights into the overall safety profile and clinical management of ADCs in the context of NSCLC treatment.
Main Methods:
- A systematic literature search was conducted across major databases (PubMed, Embase, Cochrane Library, ClinicalTrials.gov) for relevant studies.
- Data extraction focused on treatment-related adverse events (TRAEs), drug-related adverse events (AEs), and treatment-emergent adverse events (TEAEs) from included studies.
- Pooled incidence rates of TRAEs were calculated using a random-effects model, with subgroup analyses for specific toxicities and agents.
Main Results:
- Analysis of 13 studies involving 1566 NSCLC patients revealed a high overall incidence of TRAEs (93.67%).
- Grade ≥3 TRAEs occurred in 38.74% of patients, with serious TRAEs in 15.89%. Discontinuation and mortality rates were 9.52% and 0.63%, respectively.
- Fatal TRAEs were predominantly respiratory; Trastuzumab deruxtecan was linked to pneumonitis/ILD, while TROP2-targeted ADCs showed higher rates of stomatitis and ocular toxicity.
Conclusions:
- ADC monotherapy for NSCLC exhibits a high incidence of TRAEs, though most are low-grade and manageable.
- Clinical vigilance is essential due to the significant proportion of fatal TRAEs, particularly those related to respiratory toxicity.
- Close monitoring of Grade ≥3 adverse events of special interest (AESIs) is recommended for optimizing patient safety during ADC treatment.
More Related Videos
07:36Analyzing Tumor and Tissue Distribution of Target Antigen Specific Therapeutic Antibody
Published on: May 16, 2020
15:04Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation
Published on: January 19, 2019
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...